Onychomycosis

Clinics in Dermatology 28, 151-159 DOI: 10.1016/j.clindermatol.2009.12.006

Citation Report

#	Article	IF	CITATIONS
1	CaracterÃsticas clÃnicas, epidemiológicas y microbiológicas de la onicomicosis en un laboratorio de referencia, Manizales (Caldas), 2009. Infectio, 2011, 15, 168-176.	0.4	4
2	Les onychomycoses au GabonÂ: aspects cliniques et mycologiques. Journal De Mycologie Medicale, 2011, 21, 248-255.	0.7	15
4	Efficacious Treatment of Non-Dermatophyte Mould Onychomycosis with Topical Amphotericin B. Dermatology, 2011, 223, 289-292.	0.9	52
5	Electroanalysis of Cytochrome P450 3A4 Catalytic Properties with Nanostructured Electrodes: The Influence of Vitamin B Group on Diclofenac Metabolism. BioNanoScience, 2011, 1, 46-52.	1.5	17
6	Treatment of onychomycosis in Mexico. Expert Review of Dermatology, 2012, 7, 327-330.	0.3	0
7	Calcofluor White Combination Antifungal Treatments for Trichophyton rubrum and Candida albicans. PLoS ONE, 2012, 7, e39405.	1.1	34
8	Current topics in infectious diseases of the skin. Expert Review of Dermatology, 2012, 7, 93-106.	0.3	2
9	Update: medical treatment of onychomycosis. Dermatologic Therapy, 2012, 25, 582-593.	0.8	44
10	Susceptibilities of the dermatophytes Trichophyton mentagrophytes and T. rubrum microconidia to photodynamic antimicrobial chemotherapy with novel phenothiazinium photosensitizers and red light. Journal of Photochemistry and Photobiology B: Biology, 2012, 116, 89-94.	1.7	52
11	Iontophoretic drug delivery across the nail. Expert Opinion on Drug Delivery, 2012, 9, 91-103.	2.4	33
12	Systematic review of nondermatophyte mold onychomycosis: Diagnosis, clinical types, epidemiology, and treatment. Journal of the American Academy of Dermatology, 2012, 66, 494-502.	0.6	212
13	A case of onychomycosis caused by Aspergillus candidus. Medical Mycology Case Reports, 2012, 1, 45-48.	0.7	28
15	Geriatric dermatoses: a clinical review of skin diseases in an aging population. International Journal of Dermatology, 2012, 51, 509-522.	0.5	72
16	Dermatophyte susceptibility varies towards antimicrobial textiles. Mycoses, 2012, 55, 344-351.	1.8	24
17	Confocal laser scanning microscopy as a new valuable tool in the diagnosis of onychomycosis – comparison of six diagnostic methods. Mycoses, 2013, 56, 47-55.	1.8	80
18	Intermittent therapy with terbinafine and nail abrasion for dermatophyte toe onychomycosis: a pilot study. Mycoses, 2013, 56, 327-332.	1.8	15
19	Antifungal Activity of Sodium Bicarbonate Against Fungal Agents Causing Superficial Infections. Mycopathologia, 2013, 175, 153-158.	1.3	24
20	Systemic Antifungals to Treat Onychomycosis in Children: A Systematic Review. Pediatric Dermatology, 2013, 30, 294-302.	0.5	42

#	Article	IF	CITATIONS
21	Thermogelling hydrogels of cyclodextrin/poloxamer polypseudorotaxanes as aqueous-based nail lacquers: Application to the delivery of triamcinolone acetonide and ciclopirox olamine. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 83, 370-377.	2.0	55
22	Treatment of nevus spilus with Q switched Nd:YAG laser. Indian Journal of Dermatology, Venereology and Leprology, 2013, 79, 243.	0.2	6
23	Laser Therapy for Onychomycosis. Journal of Cutaneous Medicine and Surgery, 2013, 17, 301-307.	0.6	18
24	Comparison of direct microscopic methods using potassium hydroxide, periodic acid Schiff, and calcofluor white with culture in the diagnosis of onychomycosis. Indian Journal of Dermatology, Venereology and Leprology, 2013, 79, 242.	0.2	12
25	Onychomycosis in Children: An Experience of 59 Cases. Annals of Dermatology, 2013, 25, 327.	0.3	26
26	Drug Delivery to the Nail: Therapeutic Options and Challenges for Onychomycosis. Critical Reviews in Therapeutic Drug Carrier Systems, 2014, 31, 459-494.	1.2	23
28	Potential of Ergosterol Synthesis Inhibitors To Cause Resistance or Cross-Resistance in Trichophyton rubrum. Antimicrobial Agents and Chemotherapy, 2014, 58, 2825-2829.	1.4	45
29	The effect of K101 Nail Solution on <i>Trichophyton rubrum</i> and <i>Candida albicans</i> growth and ultrastructure. Mycoses, 2014, 57, 630-638.	1.8	17
30	British Association of Dermatologists' guidelines for the management of onychomycosis 2014. British Journal of Dermatology, 2014, 171, 937-958.	1.4	193
31	Molecular Determination of Mixed Infections of Dermatophytes and Nondermatophyte Molds in Individuals with Onychomycosis. Journal of the American Podiatric Medical Association, 2014, 104, 330-336.	0.2	37
32	Topical Therapy for Toenail Onychomycosis: An Evidence-Based Review. American Journal of Clinical Dermatology, 2014, 15, 489-502.	3.3	42
33	Treatment of onychomycosis with a 1,064-nm long-pulsed Nd:YAG laser. Journal of Cosmetic and Laser Therapy, 2014, 16, 165-170.	0.3	42
34	Investigational drugs for onychomycosis. Expert Opinion on Investigational Drugs, 2014, 23, 97-106.	1.9	21
35	Efinaconazole (Jublia) for the treatment of onychomycosis. Expert Review of Anti-Infective Therapy, 2014, 12, 743-752.	2.0	8
36	Tavaborole for the treatment of onychomycosis. Expert Opinion on Pharmacotherapy, 2014, 15, 1439-1448.	0.9	40
37	Combination treatment of oral terbinafine with topical terbinafine and 10% urea ointment in hyperkeratotic type tinea pedis. Mycoses, 2014, 57, 560-564.	1.8	5
38	Protocolo terapéutico empÃrico de las infecciones cutáneas. Medicine, 2014, 11, 2806-2809.	0.0	0
40	Fungal Nail Infections. Journal of Hand Surgery, 2014, 39, 985-988.	0.7	7

	Ci	CITATION REPORT	
#	ARTICLE	IF	CITATIONS
41	<i>In vitro</i> susceptibility of dermatomycoses agents to six antifungal drugs and evaluation by fractional inhibitory concentration index of combined effects of amorolfine and itraconazole in dermatophytes. Microbiology and Immunology, 2014, 58, 1-8.	0.7	51
42	<i>In vitro</i> Antifungal Activity of <i>Baccharis trimera</i> Less (DC) Essential Oil against Dermatophytes. Tropical Journal of Pharmaceutical Research, 2015, 14, 2083.	0.2	22
43	Onychomycosis in patients with chronic leg ulcer and toenail abnormalities. Anais Brasileiros De Dermatologia, 2015, 90, 136-139.	0.5	5
44	Environmental and Genetic Factors on the Development of Onychomycosis. Journal of Fungi (Basel,) T	j ETQq1 1 0.784314 r 1.5	gBT /Overic
45	Spotlight on tavaborole for the treatment of onychomycosis. Drug Design, Development and Therapy, 2015, 9, 6185.	, 2.0	35
46	Efinaconazole in the treatment of onychomycosis. Infection and Drug Resistance, 2015, 8, 163.	1.1	32
47	Treatment of Onychomycosis - a Clinical Study. Medicinski Arhiv = Medical Archives = Archives De Médecine, 2015, 69, 173.	0.4	8
48	Cytochrome P450 Enzymes and Electrochemistry: Crosstalk with Electrodes as Redox Partners and Electron Sources. Advances in Experimental Medicine and Biology, 2015, 851, 229-246.	0.8	7
49	Emerging therapies for the treatment of ungual onychomycosis. Drug Development and Industrial Pharmacy, 2015, 41, 1575-1581.	0.9	22
51	Aspergillus species as emerging causative agents of onychomycosis. Journal De Mycologie Medicale, 2015, 25, 101-107.	0.7	51
52	Fusarium spp. is able to grow and invade healthy human nails as a single source of nutrients. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 1767-1772.	1.3	27
53	Ciclopirox 8% HPCH Nail Lacquer in the Treatment of Mild-to-Moderate Onychomycosis: A Randomize Double-Blind Amorolfine Controlled Study Using a Blinded Evaluator. Skin Appendage Disorders, 2015 1, 134-140.		24
54	Antifungal therapy for onychomycosis in children. Clinics in Dermatology, 2015, 33, 333-339.	0.8	29
55	Distinct characteristics of <i>Scytalidium dimidiatum</i> and nonâ€dermatophyte onychomycosis as compared with dermatophyte onychomycosis. Journal of Dermatology, 2015, 42, 258-262.	0.6	19
56	Taurine modulates catalytic activity of cytochrome P450 3A4. Biochemistry (Moscow), 2015, 80, 366	-373. 0.7	9
57	Diagnosis and Treatment of Fungal Infections. , 2015, , .		9
58	Diagnosis of dermatophytosis: an evaluation of direct examination using MycetColor® and MycetFluo®. Diagnostic Microbiology and Infectious Disease, 2015, 83, 170-174.	0.8	14
59	Toenail Onychomycosis—A Canadian Approach With a New Transungual Treatment. Journal of Cutaneous Medicine and Surgery, 2015, 19, 440-449.	0.6	15

#	Article	IF	CITATIONS
60	Efinaconazole 10% topical solution for the topical treatment of onychomycosis of the toenail. Expert Review of Clinical Pharmacology, 2015, 8, 719-731.	1.3	19
61	A pharmaceutics perspective on drug delivery to the nail: recent advances and challenges. Therapeutic Delivery, 2015, 6, 773-775.	1.2	4
62	Molecular Identification of Candida Species Isolated from Onychomycosis in Shanghai, China. Mycopathologia, 2015, 180, 365-371.	1.3	24
63	New pharmacotherapy for the treatment of onychomycosis: an update. Expert Opinion on Pharmacotherapy, 2015, 16, 227-236.	0.9	28
64	Onychomycosis: Potential of Nail Lacquers in Transungual Delivery of Antifungals. Scientifica, 2016, 2016, 1-12.	0.6	33
65	Production of Fusaric Acid by Fusarium spp. in Pure Culture and in Solid Medium Co-Cultures. Molecules, 2016, 21, 370.	1.7	23
66	Growing Incidence of Non-Dermatophyte Onychomycosis in Tehran, Iran. Jundishapur Journal of Microbiology, 2016, 9, e40543.	0.2	29
67	Association of Nail Dystrophy With Accrued Damage and Capillaroscopic Abnormalities in Systemic Lupus Erythematosus. Journal of Clinical Rheumatology, 2016, 22, 13-18.	0.5	11
68	Nonâ€dermatophytic onychomycosis diagnostic criteria: an unresolved question. Mycoses, 2016, 59, 558-565.	1.8	18
69	Clinical study of Dermatophyte Test Strip, an immunochromatographic method, to detect tinea unguium dermatophytes. Journal of Dermatology, 2016, 43, 1417-1423.	0.6	35
70	Topical and device-based treatments for fungal infections of the toenails. The Cochrane Library, 2016, ,	1.5	2
71	Foot health in the elderly. , 2016, , 597-606.		0
72	The Antifungal Drugs Used in Skin Disease. , 2016, , 141-156.		2
73	Antibiotic and Antifungal Therapies in Dermatology. , 2016, , .		0
74	A randomised comparative study of 1064 nm Neodymiumâ€doped yttrium aluminium garnet (Nd:YAG) laser and topical antifungal treatment of onychomycosis. Mycoses, 2016, 59, 803-810.	1.8	17
75	Potential of Ravuconazole and its Prodrugs as the New OralTherapeutics for Onychomycosis. Medical Mycology Journal, 2016, 57, E93-E110.	0.5	37
76	PCR-reverse blot hybridization assay for fast and accurate identification of causative species in superficial fungal infections. Clinical and Experimental Dermatology, 2016, 41, 359-365.	0.6	6
77	A study of the treatment of cutaneous fungal infection in animal model using photoactivated composite of methylene blue and gold nanoparticle. Photodiagnosis and Photodynamic Therapy, 2016, 15, 59-69.	1.3	22

#	Article	IF	CITATIONS
78	Novel investigational therapies for onychomycosis: an update. Expert Opinion on Investigational Drugs, 2016, 25, 297-305.	1.9	29
79	Spray-dried powders improve the controlled release of antifungal tioconazole-loaded polymeric nanocapsules compared to with lyophilized products. Materials Science and Engineering C, 2016, 59, 875-884.	3.8	39
80	Efficacy of 5% amorolfine nail lacquer in <i>Neoscytalidium dimidiatum</i> onychomycosis. Journal of Dermatological Treatment, 2016, 27, 359-363.	1.1	15
81	An innovative polysaccharide nanobased nail formulation for improvement of onychomycosis treatment. European Journal of Pharmaceutical Sciences, 2017, 100, 56-63.	1.9	36
82	In vitro antifungal activity of organic compounds derived from amino alcohols against onychomycosis. Brazilian Journal of Microbiology, 2017, 48, 476-482.	0.8	13
83	Dermoscopy. , 2017, , 131-140.		1
84	Onychomycoses Due to Non-dermatophytic Molds. , 2017, , 61-71.		3
85	New Topical and Systemic Antifungals. , 2017, , 205-213.		0
86	Reversible naftifine-induced carotenoid depigmentation in Rhodotorula mucilaginosa (A. Jörg.) F.C. Harrison causing onychomycosis. Scientific Reports, 2017, 7, 11125.	1.6	18
87	Tinea Unguium: Diagnosis and Treatment in Practice. Mycopathologia, 2017, 182, 95-100.	1.3	31
88	Tavaborole, Efinaconazole, and Luliconazole: Three New Antimycotic Agents for the Treatment of Dermatophytic Fungi. Journal of Pharmacy Practice, 2017, 30, 621-630.	0.5	33
89	Major Changes in Skin Function in the Elderly and Their Contributions to Common Clinical Challenges. , 2017, , 43-53.		0
90	An Assessment of In Vitro Antifungal Activities of Efinaconazole and Itraconazole against Common Non-Dermatophyte Fungi Causing Onychomycosis. Journal of Fungi (Basel, Switzerland), 2017, 3, 20.	1.5	22
91	Singlet oxygen luminescence kinetics under PDI relevant conditions of pathogenic dermatophytes and molds. Journal of Photochemistry and Photobiology B: Biology, 2018, 178, 606-613.	1.7	13
92	Enhanced Ungual Permeation of Terbinafine HCl Delivered Through Liposome-Loaded Nail Lacquer Formulation Optimized by QbD Approach. AAPS PharmSciTech, 2018, 19, 213-224.	1.5	22
93	Update on current approaches to diagnosis and treatment of onychomycosis. Expert Review of Anti-Infective Therapy, 2018, 16, 929-938.	2.0	41
94	In vitro photodynamic inactivation (PDI) of pathogenic germs inducing onychomycosis. Photodiagnosis and Photodynamic Therapy, 2018, 24, 358-365.	1.3	20
96	Systemic Therapy of Onychomycosis. , 2018, , 185-214.		1

#	Article	IF	CITATIONS
97	Prevalence of dermatoses in patients referred for evaluation in an outpatient clinic of specialties. Anais Brasileiros De Dermatologia, 2018, 93, 513-516.	0.5	7
98	Diagnosis of Superficial Mycoses by a Rapid and Effective PCR Method from Samples of Scales, Nails and Hair. Mycopathologia, 2018, 183, 777-783.	1.3	7
99	From electrochemistry to enzyme kinetics of cytochrome P450. Biosensors and Bioelectronics, 2018, 121, 192-204.	5.3	63
100	Onychomycosis. , 2019, , 31-35.		3
101	In vitro antimicrobial effects of Hypoxis hemerocallidea against six pathogens with dermatological relevance and its phytochemical characterization and cytotoxicity evaluation. Journal of Ethnopharmacology, 2019, 242, 112048.	2.0	19
102	Allium sativum Extract Chemical Composition, Antioxidant Activity and Antifungal Effect against Meyerozyma guilliermondii and Rhodotorula mucilaginosa Causing Onychomycosis. Molecules, 2019, 24, 3958.	1.7	33
103	Recent advances in therapies for onychomycosis and its management. F1000Research, 2019, 8, 968.	0.8	30
104	Different toenail onychomycosis due to Rhodotorula mucilaginosa and Candida parapsilosis in an immunocompetent young adult. Medical Mycology Case Reports, 2019, 24, 69-71.	0.7	10
105	Formulation evaluation of ketoconazole microemulsionâ€loaded hydrogel with nigella oil as a penetration enhancer. Journal of Cosmetic Dermatology, 2019, 18, 1742-1750.	0.8	15
106	New approaches to identification and characterization of tioconazole in raw material and in pharmaceutical dosage forms. Journal of Pharmaceutical Analysis, 2019, 9, 40-48.	2.4	9
107	Bioelectrochemical Systems as Technologies for Studying Drug Interactions Related to Cytochrome P450. BioNanoScience, 2019, 9, 79-86.	1.5	12
108	Combined long-pulsed Nd-Yag laser and itraconazole versus itraconazole alone in the treatment of onychomycosis nails. Journal of Dermatological Treatment, 2020, 31, 406-409.	1.1	6
109	Onychalgia Causes and Mechanisms: The "GIFTED KID―and the "FOMITE― Skin Appendage Disorders, 2020, 6, 77-87.	0.5	2
110	The efficacy and safety of pulse vs. continuous therapy for dermatophyte toenail onychomycosis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 580-588.	1.3	13
111	Recent Patents on Permeation Enhancers for Drug Delivery Through Nails. Recent Patents on Drug Delivery and Formulation, 2020, 13, 203-218.	2.1	10
112	Onychomycosis: An Updated Review. Recent Patents on Inflammation and Allergy Drug Discovery, 2020, 14, 32-45.	3.9	51
113	Efinaconazole topical solution 10%: Formulation and efficacy assessment in the treatment of toenail onychomycosis. Mycoses, 2020, 63, 517-524.	1.8	1
114	Candida Onychomycosis: an Old Problem in Modern Times. Current Fungal Infection Reports, 2020, 14, 209-216.	0.9	7

	CHATION		
#	Article	IF	Citations
115	Dermoscopic findings of fungal melanonychia. Postepy Dermatologii I Alergologii, 2020, 37, 180-183.	0.4	5
116	Onychomycosis: a review. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1972-1990.	1.3	148
117	Fusarium infections: Epidemiological aspects over 10 years in a university hospital in France. Journal of Infection and Public Health, 2020, 13, 1089-1093.	1.9	14
118	Topical and device-based treatments for fungal infections of the toenails. The Cochrane Library, 2020, 1, CD012093.	1.5	21
119	A phase II, randomized, doubleâ€blind, placeboâ€controlled, doseâ€ranging study to evaluate the efficacy and safety of VTâ€1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail*. British Journal of Dermatology, 2021, 184, 270-280.	1.4	29
120	Methylene blueâ€mediated photodynamic therapy may be superior to 5% amorolfine nail lacquer for nonâ€dermatophyte onychomycosis. Photodermatology Photoimmunology and Photomedicine, 2021, 37, 183-191.	0.7	7
121	Systemic Antifungal Agents. , 2021, , 99-113.e4.		2
122	Onychomycosis in the Twenty-First Century: An Update on Epidemiology and Diagnosis. , 2021, , 41-64.		1
123	Prevalence and Characteristics of Onychomycosis in Patients with Knee Osteoarthritis: A Single-centre Prospective Cross-sectional Study. Acta Dermato-Venereologica, 2021, 101, adv00526.	0.6	1
124	Fractionated carbon dioxide (CO2) laser treatment contributes to trans-nail penetration of rhodamine B and changes of cytokine microenvironment. Lasers in Medical Science, 2021, 36, 1619-1623.	1.0	5
125	Novel Polypseudorotaxanes Hydrogel based Nail Lacquer of Efinaconazole for Transungual Drug Delivery. Drug Delivery Letters, 2021, 11, 52-61.	0.2	3
126	Efinaconazole topical solution (10%) for the treatment of onychomycosis in adult and pediatric patients. Expert Review of Anti-Infective Therapy, 2021, , 1-13.	2.0	2
127	The Efficacy of Phototherapy for the Treatment of Onychomycosis: An Observational Study. Photonics, 2021, 8, 350.	0.9	1
128	Fingernail onychomycosis caused by <i>Microsporum canis</i> in a teenager. Pediatric Dermatology, 2021, 38, 524-525.	0.5	2
129	Virulence Factors and Antifungal Susceptibility in Candida Species Isolated from Dermatomycosis Patients. Mycopathologia, 2021, 186, 71-80.	1.3	6
130	Dermatophyte Infections in Humans: Current Trends and Future Prospects. , 2015, , 11-35.		4
131	Comparative clinical evaluation of efficacy and safety of a formulation containing ciclopirox 8% in the form of a therapeutic nail lacquer in two different posologies for the treatment of onychomycosis of the toes. Anais Brasileiros De Dermatologia, 2012, 87, 19-25.	0.5	8
132	Repositioning the Old Fungicide Ciclopirox for New Medical Uses. Current Pharmaceutical Design, 2016, 22, 4443-4450.	0.9	41

#	Article	IF	Citations
133	Mycological Aspects of Onychomycosis in Khuzestan Province, Iran, a New Scenario as Shift from Dermatophytes towards Yeasts. Current Medical Mycology, 2017, 3, 26-31.	0.8	17
134	Total Dystrophic Onychomycosis Successfully Treated with Efinaconazole Topical Solution in Times of COVID: A Case Study. Journal of the American Podiatric Medical Association, 2021, , .	0.2	0
135	Effectiveness and safety of topical amphotericin B in 30% dimethyl sulfoxide cream versus 30% dimethyl sulfoxide cream for nondermatophyte onychomycosis treatment: A pilot study. Indian Journal of Dermatology, Venereology and Leprology, 2021, 88, 494-499.	0.2	5
136	Kurse. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2011, , 269-546.	0.0	0
137	Comparison of Therapeutic Efficacy between Lateral Type of Distal and Lateral Subungual Onychomycosis (DLSO) and Non-lateral Types of DLSO. Journal of Mycology and Infection, 2011, 16, 186-195.	0.0	0
139	Major Changes in Skin Function in the Elderly and Their Contributions to Common Clinical Challenges. , 2015, , 1-11.		0
140	CHRONIC MYCOTIC-ASSOCIATED SURGICAL NAIL PATHOLOGY COMPLICATED WITH INGROWN NAIL (NAIL) TJ ET Medicine and Medical Research, 2017, , .	⁻ Qq0 0 0 r 0.0	gBT /Overloc 0
141	Skin Manifestations Associated with HIV/AIDS. , 2018, , 835-918.		0
142	Development of a New Formulation for Onychomycosis Treatment Using Furvina® as an Active Pharmaceutical Ingredient. , 2019, , 191-203.		2
143	A Retrospective Study of Non-thermal Laser Therapy for the Treatment of Toenail Onychomycosis. Journal of Clinical and Aesthetic Dermatology, 2017, 10, 24-30.	0.1	4
145	AMPHOTERICIN B TOPICAL EXTEMPORANEOUS PREPARATIONS FOR THE TREATMENT OF NON-DERMATOPHYTIC ONYCHOMYCOSIS. Asian Journal of Pharmaceutical and Clinical Research, 0, , 135-139.	0.3	1
146	Development and Validation of HPLC Method for Efinaconazole: Application to Human Nail Permeation Studies. AAPS PharmSciTech, 2022, 23, 63.	1.5	5
147	Onikomikoz ve Tedavi Yaklaşımları. Sağlık Akademisi Kastamonu, 0, , .	0.0	0
148	Transungual Drug Delivery System for the Topical Treatment of Onychomycosis: A Review. Drug Delivery Letters, 2022, 12, 2-18.	0.2	4
149	Dermatofitoma en tinea corporis con onicomicosis de pies y manos causados por Trichophyton rubrum. Revista CientÃfica De La Facultad De Ciencias QuÃmicas Y Farmacia, 2011, 21, 44-48.	0.1	1
150	Dermatofitos y dermatofitosis: Frecuencia en Guatemala durante el periodo de mayo del 2008 a junio de 2009. Revista CientÃfica De La Facultad De Ciencias QuÃmicas Y Farmacia, 2012, 22, 19-23.	0.1	1
151	Systemic antifungal agents. , 2013, , 98-120.e3.		11

#	Article	IF	CITATIONS
153	Green formulation, characterization, antifungal and biological safety evaluation of terbinafine HCl niosomes and niosomal gels manufactured by eco-friendly green method. Journal of Biomaterials Science, Polymer Edition, 2022, 33, 2325-2352.	1.9	7
154	A clinical study spectrum of various cutaneous manifestation in geriatric age group in rural patient. International Journal of Health Sciences, 0, , 2157-2173.	0.0	0
155	Onychomycosis in Two Populations with Different Socioeconomic Resources in an Urban Nucleus: A Cross-Sectional Study. Journal of Fungi (Basel, Switzerland), 2022, 8, 1003.	1.5	1
156	Antiâ€bacterial effects of functional cosmetics containing silver ions (Ag ⁺) on problematic toenails in Republic of Korea. Journal of Cosmetic Dermatology, 2022, 21, 6005-6009.	0.8	2
157	Updated Perspectives on the Diagnosis and Management of Onychomycosis. Clinical, Cosmetic and Investigational Dermatology, 0, Volume 15, 1933-1957.	0.8	14
158	Onychomycosis in Patients with Diabetes Mellitus in Africa: A Global Scoping Review, 2000–2021. Mycopathologia, 2023, 188, 173-182.	1.3	3
159	Quality by Design Guided Development of Polymeric Nanospheres of Terbinafine Hydrochloride for Topical Treatment of Onychomycosis Using a Nano-Gel Formulation. Pharmaceutics, 2022, 14, 2170.	2.0	10
160	Onychomycosis in underrepresented groups: an all of us database analysis. Archives of Dermatological Research, 2023, 315, 647-651.	1.1	3
161	Children onychomycosis, a neglected dermatophytosis: AÂretrospective study of epidemiology and treatment. Mycoses, 2023, 66, 448-454.	1.8	3
162	A Note on the Current Status of the Trans-ungual Delivery of Poorly Soluble Drugs at a Glance: Formulation Perspective. Asian Journal of Research in Infectious Diseases, 2023, 12, 1-21.	0.0	1
163	Prevalence of Onychomycosis in Patients with Psoriasis. Current Fungal Infection Reports, 0, , .	0.9	0
164	Skin Manifestations Associated with HIV/AIDS. , 2023, , 1169-1258.		1
165	Spectroscopic (FT-IR, FT-Raman, UV-vis and NMR) Investigation, Molecular Structure, Docking and Chemical Reactivity Elucidation of Antifungal Drug Tioconazole. Polycyclic Aromatic Compounds, 0, , 1-25.	1.4	0
172	Dermatophytosis (Tinea) and Other Superficial Fungal Infections. , 2023, , 351-367.		0